Overview

Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

Status:
Not yet recruiting
Trial end date:
2025-04-28
Target enrollment:
Participant gender:
Summary
A phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer
Phase:
Phase 2
Details
Lead Sponsor:
VCN Biosciences, S.L.
Treatments:
Gemcitabine
Paclitaxel